Skepticism about the effectiveness of Western medicine in China has led to the rising popularity of Chinese patent medicine, which is considered to be less toxic and have fewer side effects. Increasingly, patients are choosing traditional Chinese medicine as their primary treatment. Additionally, the aging population and increasing health consciousness are factors contributing to industry demand. Along with the implementation of the Healthy China strategy, reforms in the medical and healthcare system have continued to deepen. The Chinese Patent Drug Manufacturing industry in China processes Chinese herbs to produce traditional Chinese patent medicine in capsule, powder, and liquid forms. Chinese traditional medicine pills are not manufactured by this industry. This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.
Table of Contents
ABOUT THIS INDUSTRY- Industry Definition
- Main Activities
- Similar Industries
- Additional Resources
- Executive Summary
- Key External Drivers
- Current Performance
- Industry Outlook
- Industry Life Cycle
- Supply Chain
- Products & Services
- Demand Determinants
- Major Markets
- International Trade
- Business Locations
- Market Share Concentration
- Key Success Factors
- Cost Structure Benchmarks
- Basis of Competition
- Barriers to Entry
- Industry Globalization
OPERATING CONDITIONS
- Capital Intensity
- Technology & Systems
- Revenue Volatility
- Regulation & Policy
- Industry Assistance
- Industry Data
- Annual Change
- Key Ratios
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Beijing TongRenTang Co., Ltd.
- Xiuzheng Pharmaceutical Group Co., Ltd.
- Tasly Pharmaceutical Group Co., Ltd.
- Guangzhou Pharmaceutical Holdings Limited
- Shandong Buchang Pharmaceuticals Co., Ltd.
Methodology
LOADING...